Thoracic Radiotherapy for Extensive Stage Small-Cell Lung Cancer: A Meta-Analysis
- PMID: 26498503
- DOI: 10.1016/j.cllc.2015.09.007
Thoracic Radiotherapy for Extensive Stage Small-Cell Lung Cancer: A Meta-Analysis
Abstract
Background: Thoracic radiotherapy (TRT) has been evaluated as a means of improving overall survival and progression-free survival in patients with extensive stage small-cell lung cancer (ES-SCLC).
Methods: A systematic review of Medline and Embase (inception to January 2015) was undertaken to identify studies of extensive stage SCLC patients receiving platinum-based chemotherapy and randomized to receive TRT versus no TRT. Studies were screened by title (n = 2343) and then abstract (n = 72), with subsequent full-text review (n = 16). Effect estimates (hazard ratios [HR] and confidence intervals) were abstracted, with a random-effects model created to estimate treatment effects. Cochrane's Q and I(2) statistics were used to assess study heterogeneity.
Results: Two randomized studies were identified, including a total of 604 patients (302 TRT; 302 non-TRT). All patients received prophylactic cranial irradiation. The weighted median age was 62 years, and 56% were male. TRT was delivered as 30 Gy/10 fractions (n = 247) or 54 Gy twice daily/36 fractions (n = 55). Overall, the delivery of TRT was associated with improved overall survival (HR, 0.81; 95% confidence interval, 0.69-0.96; P = .014) and progression-free survival (HR, 0.74; 95% confidence interval, 0.64-0.87, P < .001). For both end points, the studies were not found to be heterogeneous (P = .439 and P = .638 respectively, I(2) = 0). Bronchopulmonary toxicity (grade 3 or higher) was similar in both groups (≤ 2%). Esophageal toxicity (grade 3 or higher) was 6.6% in the TRT arm and 0% in the non-TRT arm (P < .001).
Conclusion: This systematic review with meta-analysis of 2 randomized trials indicates that TRT improves overall survival and progression-free survival in patients with extensive stage SCLC, with a small incremental risk of esophageal toxicity.
Keywords: Extensive stage; Prophylactic cranial irradiation; Small-cell lung cancer; Survival; Thoracic radiotherapy.
Copyright © 2015 Elsevier Inc. All rights reserved.
Comment in
-
Local Radiation for Extensive Stage Small Cell Lung Cancer: A Step Forward or Running in Place?Clin Lung Cancer. 2016 Jul;17(4):237-8. doi: 10.1016/j.cllc.2016.06.001. Clin Lung Cancer. 2016. PMID: 27346548 No abstract available.
Similar articles
-
Surgery for limited-stage small-cell lung cancer.Cochrane Database Syst Rev. 2017 Apr 21;4(4):CD011917. doi: 10.1002/14651858.CD011917.pub2. Cochrane Database Syst Rev. 2017. PMID: 28429473 Free PMC article.
-
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2. Cochrane Database Syst Rev. 2022. PMID: 36161421 Free PMC article.
-
Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases.Cochrane Database Syst Rev. 2012 Apr 18;2012(4):CD003869. doi: 10.1002/14651858.CD003869.pub3. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2018 Jan 25;1:CD003869. doi: 10.1002/14651858.CD003869.pub4. PMID: 22513917 Free PMC article. Updated.
-
High-Dose Versus Standard-Dose Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC: Final Survival Data, Long-Term Toxicity, and Relapse Patterns in a Randomized, Open-Label, Phase II Trial.J Thorac Oncol. 2025 Aug;20(8):1108-1119. doi: 10.1016/j.jtho.2025.04.007. Epub 2025 Apr 19. J Thorac Oncol. 2025. PMID: 40258573 Clinical Trial.
-
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450. Health Technol Assess. 2007. PMID: 17999840
Cited by
-
Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline.Pract Radiat Oncol. 2020 May-Jun;10(3):158-173. doi: 10.1016/j.prro.2020.02.009. Epub 2020 Mar 23. Pract Radiat Oncol. 2020. PMID: 32222430 Free PMC article.
-
Current and future strategies in radiotherapy for small-cell lung cancer.J Clin Transl Res. 2020 Sep 3;6(4):97-108. eCollection 2020 Oct 29. J Clin Transl Res. 2020. PMID: 33521370 Free PMC article. Review.
-
The role of radiotherapy in small cell lung cancer: a new paradigm for the radiation oncologist.Front Oncol. 2025 Jan 24;14:1541527. doi: 10.3389/fonc.2024.1541527. eCollection 2024. Front Oncol. 2025. PMID: 39927114 Free PMC article.
-
Development and validation of a nomogram for assessing survival in extensive-stage small-cell lung cancer patients with superior vena cava syndrome referred for thoracic radiotherapy: a comparison of upfront vs. consolidative approaches.Strahlenther Onkol. 2021 Dec;197(12):1072-1083. doi: 10.1007/s00066-021-01783-4. Epub 2021 Apr 28. Strahlenther Onkol. 2021. PMID: 33909099
-
Pathologic Complete Response After Neoadjuvant Chemoradiation in a Patient with Gastric Neuroendocrine Cancer.Cureus. 2019 Jul 23;11(7):e5214. doi: 10.7759/cureus.5214. Cureus. 2019. PMID: 31565618 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources